Skip to main content

Enveric Biosciences Inc(ENVB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.49
Day High5.43
Open:4.20
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Enveric Biosciences reports EB-003 receptor engagement assay data
Tipranks
Enveric Biosciences Expands At-The-Market Equity Offering Capacity
Tipranks
Enveric Biosciences Raises Capital Through Equity Offering
Tipranks
Enveric Biosciences Releases Updated Investor Presentation Materials
Tipranks
Enveric Biosciences announces issuance of U.S. patent
Tipranks
Enveric Biosciences Secures $3.1M Through Warrant Exercise
Tipranks
Enveric Biosciences Approves Key Stockholder Proposals
Tipranks
Enveric Biosciences Regains Nasdaq Compliance
Business Wire
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
Tipranks
Enveric Biosciences Plans Reverse Stock Split
Business Wire
Enveric Biosciences Announces Reverse Stock Split
Business Wire
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
Business Wire
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
Business Wire
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
Business Wire
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
Tipranks
Enveric Biosciences Closes Warrant Exercise Deal
Business Wire
Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Business Wire
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Business Wire
Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery
Business Wire
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
Tipranks
Enveric Biosciences Relocates Headquarters to Cambridge
Business Wire
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
Business Wire
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
Tipranks
Enveric Biosciences Releases New Investor Presentation
Tipranks
Enveric Biosciences Receives Nasdaq Deficiency Letter
Business Wire
Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications
Business Wire
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
Business Wire
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Business Wire
Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
Business Wire
Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
AllPennyStocks.com
This Biotech Soared On Key Announcement
This Biotech Soared On Key Announcement
Spotlight Growth
Enveric Biosciences (NASDAQ: ENVB) Obtains Notice of Allowance For a U.S. Patent Covering Its Innovative Psilocin Prodrug, EB-373

Profile

Enveric Biosciences Inc. is a patient-centric biotechnology company endeavoring to enhance the lives of Cancer Treatments with novel cannabinoid medicines. Enveric Biosciences Inc., formerly known as AMERI Holdings Inc., is based in NAPLES, Fla.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.